Possible Challenges and Appropriate Measures for a Resilient WMN-Based Disaster Network

A wireless mesh network (WMN)-based disaster network shall provide an emergency communication infrastructure in case of a catastrophe destroyed any existing communication infrastructure. Since the hardware of the disaster network is deployed in an environment affected by the outcome of a catastrophe, events such as aftershocks and/or outbreaking fires are likely to occur and may destroy the hardware of the disaster network. To maintain its provided functionality and thus its usability, the network requires to be resilient to these and other events which are affecting the network infrastructure. To achieve a resilient network, the normal state of the network as well as possible challenges affecting the normal state need to be defined in prior. This scientific work deals with the derivation and definition of the required normal state of the WMN-based disaster network, as well as the definition of possible challenges resulting from environmental-based events. Since each possible challenge is influencing the network infrastructure of the WMN-based disaster network, possible measures for preventing and/or reducing the impact of each challenge are defined. In addition, emergency corrections capable of resolving the influences of an occurring challenge are defined

High Throughput WMN for the Communication in Disaster Scenario

The Wireless mesh network (WMN) is a popular network architecture used to support disaster recovery operations. However, few research works have addressed the capacity problem of such a network. This is due to the assumption that the communication network in disaster scenario is built to support services with a low rate requirement like delay tolerant messages. At the same time, the demand for higher data rates has increased in recent years due to the digitalisation of rescue operations and the use of new services (e.g. VoIP, drones and robots). Therefore, the capacity of the WMN is becoming a central issue in the design of future WMNs. This paper proposes a Layer 1 cluster-based network to solve the throughput bottleneck in the WMN. The proposed architecture is evaluated by several real world measurements. The obtained results are compared with the theory. The proposed solution shows a throughput improvement compared to a single-radio WMN and a multi-radio WMN using the CoMTaC channel allocation strategy

Antibody responses to the full-length VAR2CSA and its DBL domains in Cameroonian children and teenagers

Additional file 2. IgG levels to VAR2CSA domains in 10–15 year old Cameroonian girls living in Ngali II and Ntouessong villages. IgG levels to VAR2CSA DBL domains and full-length protein (FV2) were measured in 11–15 year old girls residing in Ngali II and Ntouessong villages. DBL1 domain was from 3D7 strain and all the other proteins from FCR3 parasite strain. Median MFI and Inter-Quartile Range (IQR) are plotted

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow samples from 70 patients with MM using multiplexed immunofluorescence, automated microscopy and deep-learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA repair pathway and EYA3 expression in proteasome inhibitor sensitivity and major histocompatibility complex class II expression in the response to elotuzumab. Globally, ex vivo drug sensitivity associated with bone marrow microenvironmental signatures reflecting treatment stage, clonality and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for patients with MM

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease